

USSN: 10/748,524
Attorney Docket: I-1995.184 US D1
Response to Office Action of May 1, 2006

Amendments to the Claims:

1. **(Currently amended):** A multicomponent vaccine for cattle comprising an immunogenically effective combination of a protective antigen component from ~~at least~~ six clostridial organisms, a protective antigen component from at least one non-clostridial organism, which is *Moraxella Bovis* (*M. Bovis*), and ~~at least one a polymer adjuvant selected from the group consisting of oil-in-water, water-in-oil, Al(OH)₃, Al₂(SO₄)₃, AlPO₄, bacterial extracts, a plant extract, a polymer and a liposome, whereby the polymer adjuvant functions by releasing antigen slowly, and~~ wherein the vaccine is in a low dose volume of about [[2]] 3 ml or less.
2. **(Currently amended):** A multicomponent vaccine for cattle, comprising an immunogenically effective combination of protective antigen components from ~~at least~~ seven clostridial organisms, a protective antigen component from at least one non-clostridial organism, which is *M. Bovis*, and ~~at least one a polymer adjuvant selected from the group consisting of oil-in-water, water-in-oil, Al(OH)₃, Al₂(SO₄)₃, AlPO₄, bacterial extracts, a plant extract, a polymer and a liposome, whereby the polymer adjuvant functions by releasing antigen slowly, and~~ wherein the vaccine is in a low dose volume of about [[2]] 3 ml or less.

USSN: 10/748,524
Attorney Docket: I-1995.184 US D1
Response to Office Action of May 1, 2006

3. (Currently amended): The vaccine according to Claim 1, wherein the clostridial ~~organism~~
~~is organisms are~~ selected from the group consisting of *Clostridium chauvoei*, *Clostridium*
septicum, *Clostridium* *Clostridium chauvoei*, *Clostridium septicum*, *Clostridium novyi* ,
Clostridium perfringens type C, *Clostridium perfringens* type D, *Clostridium sordellii*,
Clostridium haemolyticum and *Clostridium tetani*.

Claims 4-14 (Canceled)

15. (Previously presented): The vaccine according to Claim 3, wherein the 6 clostridial
organisms are selected from the group consisting of *Cl. chauvoei*, *Cl. septicum*, *Cl. novyi*, *Cl.*
perfringens type C, *Cl. perfringens* type D, *Cl. haemolyticum* and *Cl. sordellii*.

Claim 16 (Canceled)

17. (Currently amended): The vaccine according to Claim 2, wherein the 7 clostridial
organisms are selected from the group consisting of *Cl. chauvoei*, *Cl. septicum*, *Cl. novyi*, *Cl.*
perfringens type C, *Cl. perfringens* type D, *Cl. sordellii*, *Cl. haemolyticum*, and *Cl. tetani*
Cl. chauvoei, *Cl. septicum*, *Cl. novyi*, *Cl. perfringens* type C, *Cl. perfringens* type D, *Cl.*
sordellii, *Cl. haemolyticum*, and *Cl. tetani*.

USSN: 10/748,524
Attorney Docket: I-1995.184 US D1
Response to Office Action of May 1, 2006

18. (Previously presented): The vaccine according to Claim 1, wherein the protective antigen component from 6 clostridial organisms is from *Cl. chauvoei*, *Cl. septicum*, *Cl novyi*, *Cl. perfringens* type C, *Cl. perfringens*, type D, and *Cl.sordellii*.

19. (Currently amended): The vaccine according to claim 2, wherein the protective antigen component from 7 clostridial organisms is from *Cl. chauvoei*, *Cl. septicum*, *Cl novyi*, *Cl. perfringens* type C, *Cl. perfringens* type D, *Cl. haemolyticum* and *Cl. sordellii*.

Claims 20-39 (Canceled)

40. (Currently amended): [(The)] A multicomponent vaccine according to claim 2, wherein the 7 clostridial organisms are for cattle comprising an immunogenically effective combination of the protective antigen components *Cl. chauvoei*, *Cl. septicum*, *Cl novyi*, *Cl. perfringens* type C, *Cl. perfringens* type D, *Cl. sordellii* *Cl. chauvoei*, *Cl. septicum*, *Cl novyi*, *Cl. perfringens* type C, *Cl. perfringens* type D, *Cl. sordellii*, *Cl. tetani* and *Cl. haemolyticum* *Cl. haemolyticum*, and the protective antigen component from at least one non-clostridial organism comprises *Haemophilus somnus* and, which is *M. bovis*[(.]) ,and a polymer adjuvant, whereby the polymer adjuvant functions by releasing antigen slowly, and wherein the vaccine is in a low dose volume of about 3 ml. or less.

Claims 41-45 (Canceled)

USSN: 10/748,524
Attorney Docket: I-1995.184 US D1
Response to Office Action of May 1, 2006

46. (Currently amended): A method of immunizing [[an]] a bovine animal comprising administering an effective amount of the vaccine of Claim 1.

47. (Currently amended): A method of immunizing [[an]] a bovine animal comprising administering an effective amount of the vaccine of Claim 2.

48. (New): A method of immunizing a bovine animal comprising administering an effective amount of the vaccine of claim 40.